Top Story Today
Rejected Twice, Approved Once: The Gene Therapy That Refused to Die
Every single patient survived. That was the clinical story behind Kresladi, Rocket Pharma's gene therapy for severe LAD-1, an immune disorder that kills up to 75% of untreated children before their second birthday. So why did the FDA reject it twice? Manufacturing paperwork. The drug's efficacy was never in question; the agency wanted better documentation of how it's made. After two Complete Response Letters and a full resubmission, Rocket finally cleared the hurdle. The approval also earns Rocket a Rare Pediatric Disease Priority Review Voucher, worth hundreds of millions on the open market.
Why it matters: Kresladi's long road validates that manufacturing setbacks, while painful, aren't death sentences for gene therapies with strong clinical data. It also becomes a closely watched test case for ultra-rare gene therapy commercialization in a landscape where some approved therapies have already been pulled due to low demand.
Read more →Deals and Strategy
Novartis Is Spending $2B to Replace Its Own Cash Cow
With biosimilars closing in on Xolair (a blockbuster allergy juggernaut), Novartis is paying up to $2 billion for a Phase 1 startup called Excellergy. The asset, Exl-111, doesn't just neutralize allergy-causing IgE antibodies like Xolair does; it also rips them off immune cells and shrinks the receptors that let them attach. It's the pharma equivalent of Netflix pivoting to streaming before DVD revenue collapsed.
Read more →Vertex's $4.9B Kidney Bet Just Paid for Itself
Povetacicept, the kidney drug Vertex acquired for $4.9 billion, hit its primary endpoint in Phase 3 with a 49.8% reduction in proteinuria. Analysts now project peak sales north of $4 billion annually, meaning Vertex could recoup the acquisition price every year at peak. The drug showed consistent results across all patient subgroups, a key edge over competitors. FDA filing is complete, with a potential approval around November 2026.
Read more →Clinical and Regulatory
Pfizer's Lyme Vaccine Cut Infections 73%. The Trial Still Technically Failed.
Pfizer's Lyme vaccine reduced infections by 73% in a massive Phase 3 trial, but fewer people got Lyme than expected, which widened the statistical confidence interval just enough to miss the pre-set threshold. A secondary analysis cleared the bar at 74.8% efficacy. With no Lyme vaccine on the market since 2002 and nearly 476,000 U.S. cases annually, Pfizer plans to file with regulators in 2026 anyway.
Read more →A Cancer Drug That Blocks Your Stress Hormone Just Got FDA Approved
The FDA approved Lifyorli (relacorilant), which fights platinum-resistant ovarian cancer by blocking cortisol from shielding tumors against chemo. In the Phase 3 ROSELLA trial, patients lived a median of 16 months versus 11.9 on chemo alone, a significant reduction in death risk. The mechanism is genuinely novel: no biomarker testing required, and it didn't add extra toxicity. Corcept Therapeutics now has an additional commercial product alongside Korlym.
Read more →Sarepta's $3.2M Gene Therapy Killed Kids. Now It's Testing a Fix.
After fatal liver failures in children receiving Elevidys, Sarepta is testing an enhanced immunosuppression regimen layering sirolimus on top of steroids. The ENDEAVOR trial is enrolling 25 non-ambulatory patients. The stakes extend beyond Sarepta: liver toxicity is a class-wide problem for AAV gene therapies, and this trial could define how the field manages its most dangerous flaw.
Read more →A Tiny Biotech Just Posted a 32% Response Rate Where 3% Is Normal
CytomX Therapeutics' masked ADC posted a 32% response rate in late-line colorectal cancer, a disease where single-digit responses are standard. The stock surged over 60% intraday. The drug uses a "Probody" mask that stays inactive until tumor enzymes activate it, sparing healthy tissue. CytomX plans to seek FDA alignment on a registration-enabling trial this year.
Read more →Policy, Funding, and Medtech
The $35 Insulin Bill That Could Rewrite Drug Pricing Rules
A bipartisan Senate bill would cap insulin copays at $35 per month for privately insured and uninsured Americans, closing the gap the Inflation Reduction Act left open. It also forces pharmacy benefit managers to pass 100% of rebates to plan sponsors. The real play: if Congress can cap one drug category with bipartisan support, it becomes the template for everything else.
Read more →$89M Says Your Next Injection Could Be a Pill
Pinnacle Medicines raised $89 million to engineer peptide drugs that survive your stomach, no injection required. The oral GLP-1 market alone could reach massive scale over the next decade. Pinnacle uses AI-driven molecular design to build durability into the peptide itself, rather than just wrapping it in a coating. The round was oversubscribed; clinical proof-of-concept studies are next.
Read more →A $3B Startup Just Rolled Into Intuitive Surgical's Territory
CMR Surgical launched its Versius Plus robotic surgery system in the U.S., directly challenging Intuitive Surgical's $10 billion empire. The pitch: modular arms that wheel between operating rooms instead of being bolted to one. With $1.32 billion raised and 45,000 global procedures completed, CMR is targeting hospitals priced out of the da Vinci model.
Read more →